Project Grant R01DA061243
Award Date
7/15/24
Completion Date
5/31/29
Dollars Obligated
$1.4M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
This federal Project Grant award of $1,243,350.00, issued by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to investigate the mechanisms underlying sleep disturbances associated with opioid withdrawal. The key objectives of this 5-year project are to: 1) determine how spontaneous withdrawal from chronic morphine administration disrupts the neuronal activity and membrane properties of wake-active noradrenergic...
This $1,331,649 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the bidirectional relationship between circadian rhythms and cannabinoid use. The research will utilize a rat model to determine how cannabinoid self-administration affects cell type-specific molecular rhythms in the nucleus accumbens (NAc) and associated impacts on sleep/wake patterns. The team will then assess whether...
This $2,185,966 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the relationship between short sleep duration and vulnerability to methamphetamine addiction. The research, conducted by the University of Mississippi Medical Center, will evaluate the role of orexin (hypocretin) dysregulation in driving the short sleep phenotype observed in female rhesus monkeys. The project will...
This federal Project Grant award of $1,523,422.00 was issued by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award will fund a research study to investigate the role of the orexin system at the intersection of opioid use disorder (OUD) and insomnia. The study aims to examine the effects of the dual orexin receptor antagonist lemborexant on sleep, reward, negative emotionality, and metacognition among individuals with OUD...
The $858,600 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to identify and validate G protein-coupled receptors (GPCRs) expressed by somatostatin-expressing inhibitory neurons in the prefrontal cortex as potential targets for developing novel treatments for opioid use disorder (OUD). The research aims to take an unbiased transcriptomics approach to identify GPCR transcripts in these...
This federal Project Grant award of $2,264,782 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support a research study examining the effects of cannabis use and discontinuation on sleep, circadian rhythms, and light sensitivity in 60 emerging adults (ages 18-25) who regularly use cannabis. The study, to be conducted at the University of Pittsburgh, will assess participants' homeostatic sleep drive and circadian...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $751,043 to the University of Massachusetts Medical School to investigate the cellular and molecular mechanisms underlying the co-occurrence of opioid use disorder (OUD), major depressive disorder (MDD), and HIV in the human brain. The research will use a combination of single-cell sequencing technologies, such as single-nucleus RNA-sequencing...
This federal Project Grant award of $1,704,286 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to uncover the biological basis for why sleep apnea patients are more sensitive to opioid-induced respiratory depression (OIRD), which is a leading cause of death from opioid overdose. The key objectives are to investigate how deficient oxytocin neurotransmission from the paraventricular nucleus of the hypothalamus (PVH)...
The National Institute on Drug Abuse (NIDA) awarded a $1,039,420 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Medical University of South Carolina (MUSC). The 5-year grant, running from June 1, 2025 to February 28, 2030, will support research aimed at characterizing the transcriptomic profiles and causal functions of specific neuronal ensembles within key brain circuits that govern the facilitation and disinhibition of alcohol and opioid seeking...
This federal Project Grant award for $1,076,036 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to characterize the electroencephalography (EEG) signatures associated with prefrontal cortex (PFC) interneuron function in the context of opioid use disorder (OUD). The key objectives are to: 1) Examine how individual differences in PFC theta power and interneuron physiology correlate with fentanyl self-administration and...